Citation Impact
Citing Papers
Benefit of farnesoid X receptor inhibition in obstructive cholestasis
2006
X-linked cholestasis in mouse due to mutations of the P4-ATPase ATP11C
2011 StandoutNobel
Colorectal cancer statistics, 2020
2020 Standout
Farnesoid X Receptor Expression Is Decreased in Colonic Mucosa of Patients with Primary Sclerosing Cholangitis and Colitis-associated Neoplasia
2013
Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTα-OSTβ in cholestasis in humans and rodents
2006
CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus
2015 StandoutNatureNobel
Colorectal cancer statistics, 2023
2023 Standout
Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases
2013
Postnatal Deletion of Fat Storage-inducing Transmembrane Protein 2 (FIT2/FITM2) Causes Lethal Enteropathy
2015
Bile acid transporters
2009
Bile acid transporters and regulatory nuclear receptors in the liver and beyond
2012
Analysis of the In Vivo Functions of Mrp3
2005
Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease
2012
Deficiency of liver Comparative Gene Identification-58 causes steatohepatitis and fibrosis in mice
2013
Oxidative and electrophilic stress induces multidrug resistance–associated protein transporters via the nuclear factor-E2–related factor-2 transcriptional pathway
2007
NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer
2009 Standout
Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis
2017 Standout
Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist
2013 Standout
New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond
2015
The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis
2008
Oxidative stress, inflammation, and cancer: How are they linked?
2010 Standout
Tissue-specific actions of FXR in metabolism and cancer
2014
Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress
2008
Genome‐wide tissue‐specific farnesoid X receptor binding in mouse liver and intestine†
2009
A robust cell culture system supporting the complete life cycle of hepatitis B virus
2017 StandoutNobel
Role of the Intestinal Bile Acid Transporters in Bile Acid and Drug Disposition
2010
Microbes, Microbiota, and Colon Cancer
2014
Burden of liver diseases in the world
2018 Standout
The gut microbiota, bacterial metabolites and colorectal cancer
2014 Standout
Intestinal transport and metabolism of bile acids
2014
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
2013 StandoutNature
Alterations in xenobiotic metabolism in the long‐lived Little mice
2007
Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease
2010
The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-α and -β genes
2005
PXR Prevents Cholesterol Gallstone Disease by Regulating Biosynthesis and Transport of Bile Salts
2011
Marine natural products
1990 Standout
Hepatic inflammation and progressive liver fibrosis in chronic liver disease
2014
Bile Acids Induce Inflammatory Genes in Hepatocytes
2011
The Role of the Sodium-Taurocholate Cotransporting Polypeptide (NTCP) and of the Bile Salt Export Pump (BSEP) in Physiology and Pathophysiology of Bile Formation
2010
Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis
2015
Targeting oxidative stress in disease: promise and limitations of antioxidant therapy
2021 Standout
Bile Acid Metabolism and Signaling
2013
The biology and function of fibroblasts in cancer
2016 Standout
Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics
2014 Standout
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
2009
Farnesoid X Receptor Critically Determines the Fibrotic Response in Mice but Is Expressed to a Low Extent in Human Hepatic Stellate Cells and Periductal Myofibroblasts
2009
Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity
2010
A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors
2019 StandoutNobel
CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice†
2005
The Role of Canalicular ABC Transporters in Cholestasis
2014
The RNA Sensor RIG-I Dually Functions as an Innate Sensor and Direct Antiviral Factor for Hepatitis B Virus
2014 StandoutNobel
Molecular mechanisms of cisplatin resistance
2011 Standout
Gut microbiome and health: mechanistic insights
2022 Standout
Is right-sided colon cancer different to left-sided colorectal cancer? – A systematic review
2014
Bile Acid Signaling in Metabolic Disease and Drug Therapy
2014
Primary Sclerosing Cholangitis
2016
Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma
2014 StandoutNobel
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
2016 Standout
Targeting multidrug resistance in cancer
2006 Standout
FXR signaling in the enterohepatic system
2012
Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
2013
Diet–microbiota interactions as moderators of human metabolism
2016 StandoutNature
Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity
2015
Individual bile acids have differential effects on bile acid signaling in mice
2015
A within-trial cost-effectiveness analysis of primary care referral to a commercial provider for weight loss treatment, relative to standard care—an international randomised controlled trial
2012 Standout
Dynamics and functions of lipid droplets
2018 Standout
Novel insight into mechanisms of cholestatic liver injury
2012
24-norUrsodeoxycholic Acid Is Superior to Ursodeoxycholic Acid in the Treatment of Sclerosing Cholangitis in Mdr2 (Abcb4) Knockout Mice
2006
Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid
2005
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
2014 Standout
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice
2008
Silybin exerts antioxidant effects and induces mitochondrial biogenesis in liver of rat with secondary biliary cirrhosis
2014
Colorectal Cancer-Associated Fibroblasts are Genotypically Distinct
2014
The Nrf2 regulatory network provides an interface between redox and intermediary metabolism
2014 Standout
REGULATION OF DRUG TRANSPORTERS: DURING INFECTION AND INFLAMMATION
2007
Hallmarks of Cellular Senescence
2018 Standout
Bile acid signaling through farnesoid X and TGR5 receptors in hepatobiliary and intestinal diseases
2015
CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus
2015 StandoutNobel
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism
2016 Standout
Regulation of Hepatic Cytochromes P450 by Lipids and Cholesterol
2011
Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA
2015 StandoutNobel
Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management
2013
The impact of the endoplasmic reticulum protein-folding environment on cancer development
2014
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Drug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis
2006
Curcumin activates Wnt/β-catenin signaling pathway through inhibiting the activity of GSK-3β in APPswe transfected SY5Y cells
2011
Marine sponge steroids as nuclear receptor ligands
2012
Bile acid receptors as targets for drug development
2013
Tissue-specific function of farnesoid X receptor in liver and intestine
2011
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
2008 Standout
Gut microbiota in human metabolic health and disease
2020 Standout
Primary sclerosing cholangitis – a comprehensive review
2017
Update on primary sclerosing cholangitis
2013
Nuclear receptors as therapeutic targets in cholestatic liver diseases
2008
A Fibrosis‐Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis
2020 StandoutNobel
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Deciphering the nuclear bile acid receptor FXR paradigm
2010
Nuclear Receptor Ligands: Rational and Effective Therapy for Chronic Cholestatic Liver Disease?
2005
Hepatic Transcript Levels for Genes Coding for Enzymes Associated with Xenobiotic Metabolism are Altered with Age
2007
Mechanisms of Insulin Action and Insulin Resistance
2018 Standout
Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism
2010
Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems
2014 StandoutNobel
Role of Nuclear Receptors in the Adaptive Response to Bile Acids and Cholestasis: Pathogenetic and Therapeutic Considerations
2006
Bile Salt Transporters: Molecular Characterization, Function, and Regulation
2003
Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury
2005
Colorectal cancer statistics, 2017
2017 Standout
FXR silencing in human colon cancer by DNA methylation and KRAS signaling
2013
Embryonic Lethality and Fetal Liver Apoptosis in Mice Lacking All Three Small Maf Proteins
2011
The First Total Synthesis of Solomonsterol B, a Marine Pregnane X Receptor Agonist
2012
The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis
2018 Standout
The Role of Oxidative Stress and Antioxidants in Liver Diseases
2015 Standout
Inflammatory responses and inflammation-associated diseases in organs
2017 Standout
Host-Gut Microbiota Metabolic Interactions
2012 StandoutScience
Intrahepatic cholestasis of pregnancy
2009
Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma
2010
REGULATION OF DRUG-METABOLIZING ENZYMES AND TRANSPORTERS IN INFLAMMATION
2005
Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus
2012 Standout
Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells
2013 StandoutNobel
Discovery of 6α-Ethyl-23(S)-methylcholic Acid (S-EMCA, INT-777) as a Potent and Selective Agonist for the TGR5 Receptor, a Novel Target for Diabesity
2009
The Essential Medicinal Chemistry of Curcumin
2017 Standout
Extending Healthy Life Span—From Yeast to Humans
2010 StandoutScience
Bile Acids as Metabolic Regulators and Nutrient Sensors
2019
Bile Salt Transporters
2002
Works of Dagmar Silbert being referenced
Fxr−/− mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids
2005
Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine
2003
Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis
2007
The role of the hepatocyte cytokeratin network in bile formation and resistance to bile acid challenge and cholestasis in mice #
2009
Absence of adipose triglyceride lipase protects from hepatic endoplasmic reticulum stress in mice
2012
Curcumin improves sclerosing cholangitis in Mdr2 −/− mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation
2010
Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2 −/− ( Abcb4 −/−) mouse cholangiopathy model by promoting biliary HCO Symbol output
2011
Differential effects of norUDCA and UDCA in obstructive cholestasis in mice
2013
Hepatobiliary transporter expression in human hepatocellular carcinoma
2005
Complementary Stimulation of Hepatobiliary Transport and Detoxification Systems by Rifampicin and Ursodeoxycholic Acid in Humans
2005
Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis
2003
Hepatobiliary Transporter Expression in Intercellular Adhesion Molecule 1 Knockout and Fas Receptor-Deficient Mice after Common Bile Duct Ligation Is Independent of the Degree of Inflammation and Oxidative Stress
2007
Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice
2003
Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver
2005
Impact of experimental colitis on hepatobiliary transporter expression and bile duct injury in mice
2009
Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis
2011
Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2 −/− mice†‡§
2009
Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-α/β in the adaptive response to bile acids
2005
Combined Rifampicin and Ursodeoxycholic Acid Treatment Does Not Amplify Rifampicin Effects on Hepatic Detoxification and Transport Systems in Humans
2012
Alterations in Lipid Metabolism Mediate Inflammation, Fibrosis, and Proliferation in a Mouse Model of Chronic Cholestatic Liver Injury
2011
Alterations of hepatobiliary transporter expression in primary biliary cirrhosis (PBC)
2002
Role of nuclear bile salt receptors Fxr and Pxr in mediating adaptive hepatobiliary transporter response to cholic acid (CA) in mouse liver
2003
Induction of short heterodimer partner 1 precedes downregulation of Ntcp in bile duct-ligated mice
2002
Complementary Stimulation of Hepatobiliary Transport and Detoxification Systems by Rifampicin and Ursodeoxycholic Acid in Humans
2005
70 Differential effects of ursodeoxycholic acid (UDCA) and cholic acid (CA) on hepatic and renal expression of MRP4 and MRP6, two novel ABC transporters, in mice
2004